The Annual Meeting will be the 19th meeting and will be open to anyone who wants to participate. It will be held virtually and in person between October 22 and 25
California, June 29, 2023 – The Society for Oligonucleotide Therapeutics (OET) is pleased to bring together those in the field of oligonucleotide therapeutics for its 19th Annual Oligonucleotide Meeting. Anyone interested in oligonucleotide therapeutics is invited to participate in the event, which will be held virtually and in person from October 22-25, 2023 in Barcelona, Spain.
OTS is a non-profit, open forum that promotes academic and industrial research and development of oligonucleotide therapies. At this year's meeting, leaders from around the world will present with students on topics ranging from antisense, siRNA, immunostimulatory and aptamer applications, RNA/DNA editing, mRNA therapeutics, and basic RNA research.
This year's keynote speaker will be Dr. David Liu of the Broad Institute of Harvard and MIT. Liu is known for inventing base editing, a tool for precisely modifying DNA, as well as primary editing, PACE, and DNA-based synthesis, technologies used by thousands of laboratories around the world. He has been elected to the National Academy of Sciences, the National Academy of Medicine, and the American Association for the Advancement of Science. Liu has published more than 225 articles and is the inventor of more than 90 US patents.
OTS is privileged to present its Lifetime Achievement Awards, with the 2022 Award going to Sudhir Agrawal, D.Phil, a key player in the discovery and development of RNA therapies and co-inventor of over 400 patents worldwide. . As Chairman and Founder of ARNAY Sciences LLC, his company's pioneering publications helped establish antisense as a new drug discovery platform and have contributed to critical discoveries in antisense gapmer and exon skipping.
The 2023 Lifetime Achievement Award will be presented to Cy Stein, MD, PhD, who has more than three decades of experience treating patients with prostate and genitourinary cancer. Throughout her career, Stein has blended her love of science with her passion for caring for patients and hopes to continue to do so for many years to come. Her four decades of scientific research have been devoted primarily to the development of new cancer drugs.
As the area of oligonucleotide therapeutics continues to prosper and evolve, OET will continue to support this vital work, and its annual meeting will serve as a dialogue and debate between industry, academia and health authorities to educate and share their advances. Currently, more than 100 oligonucleotide treatments are in development for common and rare conditions, such as cancer and Alzheimer's disease, and several have received regulatory approval.
OTS looks forward to seeing attendees in person or online. In-person registration will be closed to 750 delegates, so early registration is recommended for those wishing to attend in person.
Those interested in attending can consult more information at 2023oligomeeting.com or register here.
Contact
Contact Name: Geri Beaty
Contact phone: (619) 795-9458
